Benralizumab in the Treatment of Patients With Severe Asthma With ABPA

Status Withdrawn

Clinical Trial Summary

Phase IV, open-label study will evaluate effects of Benralizumab in the treatment of severe asthma in patients with allergic bronchopulmonary aspergillosis

Clinical Trial Description

Subjects who have been identified to have severe asthma with ABPA will be consented and enrolled in the study to receive benralizumab injections administered every 4 weeks for the first 3 injections with an additional injection eight weeks to follow for a total of 16 weeks active treatment with a follow-up/termination visit eight weeks from the last injection. The termination visit will occur week 24 for subjects who complete the study treatment. Subjects who receive the first dose of benralizumab but withdraw from the study or terminate study treatment for any reason should complete all the procedures outlined for the termination visit. ;

Study Design

Related Conditions & MeSH terms

ABPA
Allergic Bronchopulmonary Aspergillosis
Aspergillosis
Asthma
Pulmonary Aspergillosis
Severe Asthma

Clinical Trial Details

NCT number	NCT04108962
Study type	Interventional
Source	Baylor Research Institute
Contact
Status	Withdrawn
Phase	Phase 4
Start date	December 23, 2019
Completion date	October 1, 2021

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT05018299` - Evaluate the Efficacy and Safety of FB704A in Adult With Severe Asthma	Phase 2
Recruiting	`NCT05472324` - Evaluate the Efficacy and Safety of TQC2731 Injection in Patients With Severe Asthma.	Phase 2
Recruiting	`NCT04914078` - Severe Asthma Exacerbations and Mepolizumab Treatment
Completed	`NCT05576454` - Evaluate the Pharmacokinetics of BAT2606 Injection in Healthy Chinese Male Subjects	Phase 1
Recruiting	`NCT04520165` - Effect of Biologicals on Alternative Functions of Eosinophils in Severe Asthma
Recruiting	`NCT04438408` - National Survey on Care Pathway and Quality of Life in Patients With Severe Asthma According to Their Phenotype.
Not yet recruiting	`NCT04463836` - Phenotyping Circulating and Lung Resident Eosinophils in Severe Asthma (P-CLESA)
Recruiting	`NCT03377920` - Predictive Value of Spirometric PIF to Produce PIF Rate Needed for the Use of Current DPI's.	N/A
Recruiting	`NCT04565483` - Predictive Signature of Benralizumab Response	Phase 4
Recruiting	`NCT04045587` - International Severe Asthma Registry: Canadian Cohort
Completed	`NCT05616338` - Modeling Bronchial Epithelium in Severe Asthma With Human Induced Pluripotent Stem Cells (iPSC)	N/A
Active, not recruiting	`NCT02038374` - Clinico-biological Correlation of Severe Asthma in Children	N/A
Active, not recruiting	`NCT02114034` - Cohort Analysis of Clinical and Biological Severe Childhood Asthma
Recruiting	`NCT06035289` - Register Schweres Asthma - German Asthma Net e.V.
Not yet recruiting	`NCT03532685` - Clinical, Inflammatory and Functional Evaluation of a Population of Severe and Obese Asthmatics: Follow up	N/A
Completed	`NCT03931954` - Prevalence of the Eosinophilic Phenotype Among Severe Asthma Patients
Recruiting	`NCT03984253` - Swiss Severe Asthma Register
Recruiting	`NCT03435237` - Phenotyping Asthma for Bronchial Thermoplasty
Recruiting	`NCT03476109` - Study of Magnitude and Prediction of Response to Omalizumab and Mepolizumab in Adult Severe Asthma.	Phase 4
Recruiting	`NCT04714567` - Portuguese Severe Asthma Registry: Getting Answers for Severe Asthma Patients